Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:small_molecule
gptkb:drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1204669-58-8
|
| gptkbp:chemicalFormula |
C11H13BrFN7O4S
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2018)
|
| gptkbp:developedBy |
gptkb:Incyte_Corporation
|
| gptkbp:failedLaunches |
gptkb:ECHO-301/KEYNOTE-252_trial
|
| gptkbp:intendedUse |
gptkb:immunotherapy
|
| gptkbp:isInvestigational |
true
|
| gptkbp:IUPACName |
N-(3-bromo-1H-indazol-6-yl)-6-fluoro-3-(pyridin-2-ylmethylamino)pyridine-2-carboxamide
|
| gptkbp:mechanismOfAction |
IDO1 inhibitor
|
| gptkbp:molecularWeight |
456.23 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:INCB024360
|
| gptkbp:target |
gptkb:indoleamine_2,3-dioxygenase_1
|
| gptkbp:bfsParent |
gptkb:IDO1
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
epacadostat
|